NCT06776172Recruiting
Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
Summary
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
Inclusion criteria
• Age ≥ 18 years and life expectancy \>15 years • Any biopsy-proven WHO/ISUP grade groups III-V PCa • High-risk prostate cancer defined as: • Any biopsy-proven WHO/ISUP grade group III-V PCa or • ISUP grade group II and PSA \> 20 ng/ml • PSMA-PET: negative staging for regional and distant metastasis • multidisciplinary tumorboard recommendation for radical prostatectomy • WHO performance status 0-1 • Adequate condition (ASA ≤ III) for general anesthesia and RP
Exclusion criteria
• ISUP grade group I PCa and cT1 or cT2 (MRI) • cT4 (MRI) PCa • PSMA-PET: positive staging for local and distant metastasis • Any prior neoadjuvant, local or systemic treatment for PCa • Previous PLND or pelvic radiotherapy • Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence. • Any other serious underlying medical, psychiatric, psychological, familial, or geographical • condition, which in the judgment of the investigator may interfere with the planned • staging, treatment and follow-up, which affect patient compliance or place the patient at • high risk from treatment-related complications. • Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study.
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- No phase (N/A)
- Study type
- Interventional
- Countries
- Switzerland
- Sponsor
- University Hospital, Basel, Switzerland(Other)
- Protocol no.
- 2024-02381; bb24Rentsch2
- Conditions
- Prostate Cancer Surgery, Prostate Cancers
- Interventions
- Procedure
Treatments studied
- Extended Pelvic Lymph Node Dissection
Locations · 15
- Aarau, SwitzerlandCantonal Hospital AarauRecruiting at this site
- Basel, SwitzerlandUniversity Hospital BaselRecruiting at this site
- Bern, SwitzerlandInselspitalRecruiting at this site
- Bern, SwitzerlandLindenhof HospitalRecruiting at this site
- Biel, SwitzerlandCantonal Hospital BielRecruiting at this site
- Chur, SwitzerlandCantonal Hospital ChurRecruiting at this site
- Geneva, SwitzerlandUniversity Hospital GenevaRecruiting at this site
- Lausanne, SwitzerlandCentre hospitalier universitaire vaudois (CHUV)Recruiting at this site
- Liestal, SwitzerlandCantonal Hospital LiestalRecruiting at this site
- Lucerne, SwitzerlandCantonal Hospital LuzernRecruiting at this site
- Lugano, SwitzerlandOspedale Regionale di LuganoRecruiting at this site
- Neuchâtel, SwitzerlandCantonal Hospital NeuchâtelRecruiting at this site
- Sankt Gallen, SwitzerlandCantonal Hospital St. GallenRecruiting at this site
- Zurich, SwitzerlandHospital Triemli, ZürichRecruiting at this site
- Zurich, SwitzerlandUniversity Hospital ZürichRecruiting at this site
In total, worldwide, all 15 sites listed in the registry are recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: July 3, 2025).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other identifiers
- KFS-5775-02-2023 · other grant
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.